Ocugen's COVID-19 Vaccine Partner To Charge Twice As Much As Main Indian Rival Astrazeneca

Retrieved on: 2021-04-26 06:00:00

Tags for this article:

Click the tags to see associated articles and topics

Ocugen's COVID-19 Vaccine Partner To Charge Twice As Much As Main Indian Rival Astrazeneca. View article details on hiswai:

Excerpt

Price Action: Ocugen shares closed almost 3.7% higher on Friday at $9.63, while AstraZeneca's shares closed almost 0.9% lower at $52.26.

Article found on: www.benzinga.com